期刊文献+

雷公藤治疗类风湿关节炎的疗效和生活质量评价 被引量:14

Assessment on Life Quality of Patients with Rheumatoid Arthritis and Efficacy of Tripterygium Wilfordii Hook
下载PDF
导出
摘要 目的以甲氨喋呤(MTX)为对照,观察接受雷公藤治疗的类风湿关节炎患者的生活质量和疗效,旨在科学地评价雷公藤在治疗类风湿关节炎中的作用。方法80例活动性类风湿关节炎患者按1∶1比例随机分入雷公藤组和MTX组,分别服用雷公藤片6片d/,MTX10mg/周,共12周,治疗前后分别测定临床指标及填写类风湿关节炎生活质量量表。结果74例病人完成治疗,雷公藤组总有效率为84.2%,副反应发生率为25.6%,M TX组总有效率为86.6%,副反应发生率为22.2%,两组差异无统计学意义。雷公藤能明显提高患者生活质量,但与MTX比较差异无统计学意义。结论雷公藤治疗类风湿关节炎疗效肯定,并且能改善患者生活质量。 Objective To assess the quality of life (QOL) in the patients with rheumatoid arthritis (RA) and clinical efficacy of Tripterygium Wilfordii Hook(TWH) therapy compared with methotrexate (MTX). Methods 80 patients with active RA were divided randomly into TWH group and MTX group respectively. The patients in TWH group received six tablets of TWH per day and in MTX group received MTX 10mg per week, all the treatment was finished in 12 weeks. The clinical and laboratory parameters and the questionnaire for assessment of QOF were analysed before and after treatment for every patient. Results The total effective rates was 84.2% and 86.6% in TWH and MTX groups respectively, the incidence rate of side effect was 25.6% in TWH group and 22.2% in MTX group in all 74 patients who finished the treating course, in which there was no significant difference between two groups. TWH could improve the quality of life of the patients, but there was no significant difference between TWH and MTX. Conclusion TWH therapy is effective for patients with RA and can improve QOF of the patiets.
出处 《湖南中医学院学报》 CAS 2006年第2期25-27,共3页 Journal of Hunan College of Traditional Chinese Medicine
基金 国家自然科学基金资助项目(No.90209049)
关键词 雷公藤 类风湿关节炎 临床疗效 生活质量 评价 Tripterygium Wilfordii Hook rheumatoid arthritis curative effect life quality assessment
  • 相关文献

参考文献8

二级参考文献17

  • 1费立鹏 Henderson G.医学社会科学的临床应用:医学社会科学在临床科研的设计和评价中的使用[M].上海临床流行病中心,1997..
  • 2Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clin Trials, 1996, 17: 1-12.
  • 3Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet, 1998, 352: 609-613.
  • 4Clarke M,Oxman AD.Cochrane Collaboration Handbook.李静,罗德成,方芳,等,译.中国Cochrane中心培训教材.成都:华西医科大学,1998.10.
  • 5费立鹏,医学社会科学的临床应用.医学社会科学在临床科研的设计和评价中的使用,1997年
  • 6Barlett RR, Anagnpstopulos H, Zielinski T et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathal, 1993; 14(4):381~394
  • 7MldEnovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with rheumatoid arthritis. Arthritis Rheum, 1995; 38(11):1596~1603
  • 8Felson DT, Anderson JJ, Boers M et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995; 38(6):727~735
  • 9Choy EH, Scott DL. Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. Drugs, 1997; 53(3):337~348
  • 10Xu X, Williams JW, Gong H et al. Two activities of the immunosuppressive metabolite of leflunomide,A17 1726. Inhibition of pyrimidine nucleotide synthesis synthesis and protein tyrosine phosphorylation. Biochem Pharmacol, 1996;52(4):527~534

共引文献409

同被引文献236

引证文献14

二级引证文献140

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部